COVID-19 limitations unique opportunity for researchers to decrease digital divide

April 29, 2020

The COVID-19 shelter-in-place orders and other limitations could offer researchers the chance to use technology to decrease the digital divide and disparities in academic research, suggests a University of California, Davis, professor in a new commentary.

"While I know many of my colleagues are frustrated with this pause in clinical research, it is actually a unique opportunity," said Leigh Ann Simmons, chair of the Department of Human Ecology, whose research interests include increased equity in health care delivery and chronic disease prevention in rural areas. "People who live in rural areas are often left out of clinical trials that can benefit them, partly because they are not near large medical centers," she said. This includes migrant workers, farmers and the general public who live in outlying areas.

She is co-author of the commentary, "Navigating Nonessential Research Trials During COVID 19: The Push We Needed for Using Digital Technology to Increase Access for Rural Participants?" published in The Journal of Rural Health earlier this month. Co-author is Devon Noonan, a researcher at Duke University.

Simmons said some research in which research subjects have to be contacted personally for interviews, testing or surveys has stopped since social distancing went into effect. This is a mistake, she said. "If we think creatively we can extend our reach."

"We need to stop and think," said Simmons, who is herself currently engaged in two rural health prevention studies that are being conducted solely using remote strategies. "How can we do our work remotely? Is there a way to get our data without human contact? And if we go this route, how can we include people who may not usually participate in our studies?"

It is well known, the authors said in their paper, that rural populations experience significant health disparities, especially in rates of common chronic diseases such as heart disease, diabetes, cancer and the associated health behaviors such as diet, physical activity, and tobacco and other substance use. "These disparities are in part due to rural residents' lack of access to, knowledge about, and participation in clinical trials," they said.

Participation in such trials is made more difficult in these areas too by lack of good internet access. Simmons said this could be augmented by researchers using community centers or regional facilities, or other community partners, to enable access for those in the study. Regional facilities could also be used to help with data and sample collections.

Further, state departments of heath "could replicate the partnership that the California Department of Education initiated with Google to distribute mobile hotspots to areas without broadband access so that K-12 education could continue amid school closures associated with shelter-in-place orders," the authors suggest.

"Moving to remote clinical trials is not without its challenges, especially for studies that are well underway," she emphasizes. "Importantly, the steps we take now to continue nonessential research remotely may provide the evidence we need to ensure that future studies target these hard-to-reach populations for study inclusion."

Establishing remote access to clinical trials will serve to not only decrease rural clinical trial disparities, the authors said, but also to promote rural health equity into the next decade and beyond.
-end-
Read the commentary: https://onlinelibrary.wiley.com/doi/epdf/10.1111/jrh.12446

University of California - Davis

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.